FMBA of Russia’s Leitragin, an inhaler drug that prevents cytokine storm, one of the severe complications of COVID-19, has shown its effectiveness in the third phase of clinical trials. The drug reduces the recovery time and duration of hospitalization by 1.5 times, the press service of the department states.
Clinical trials also confirmed the safety of the drug: no serious side effects were registered in the group of patients who were administered Leitragin.
The Ministry of Health of the Russian Federation registered Leitragin on May 25, 2021. Previously, scientists experimentally showed that the drug is able to reduce HMGB1 levels in acute lung damage, thereby preventing a cytokine storm.
